The CiPA initiative began following a workshop in July 2013 at the US FDA. The objective of the CiPA initiative was to engineer an assay for assessment of the proarrhythmic potential of new drugs with improved specificity compared with the hERG assay plus Thorough QT study.
A CiPA Steering Team comprised of international regulators, industry, academics and nonprofits oversaw the four main work streams:
All work streams concluded novel data generation efforts and have published their work (see more here .)